Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 4Multiple Myeloma 3Medulloblastoma 3Stomach Neoplasms 2Prostatic Neoplasms 2Lymphoma 2Chondrosarcoma 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Melanoma 1Malignant mesenchymal tumor 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1

Interventions

Cyclophosphamide 62Vincristine 45Doxorubicin 43Etoposide 42Rituximab 37Prednisone 31Filgrastim 31Biopsy 27Peripheral Blood Stem Cell Transplantation 25Cytarabine 24Radiotherapy 22fludarabine phosphate 19Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 18Prednisolone 17Melphalan 16Ifosfamide 14Dexamethasone 14Bleomycin 13Leucovorin 12Cyclosporine 12Carmustine 12sargramostim 11Cisplatin 10Vinblastine 8Chlorambucil 8Busulfan 8fludarabine 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma × HhAntag691 × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06357988 2026-05-28

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡